Veeva Systems (VEEV) Q2 2021 Earnings Call Transcript

Veeva Systems (VEEV 0.91%)
Q2 2021 Earnings Call
Aug 27, 2020, 4:30 p.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by, and welcome to Veeva Systems fiscal 2021 second-quarter results conference call. [Operator instructions] I would now like to hand the conference over to Rick Lund, head of investor relations. Thank you. Please go ahead.

Rick Lund -- Head of Investor Relations

Good afternoon, and welcome to Veeva's fiscal 2021 second-quarter earnings call for the quarter ended July 31, 2020. With me on today's call are Peter Gassner, our chief executive officer; Paul Shawah, SVP of commercial cloud; and Tim Cabral, our chief financial officer. During the course of this conference call, we will make forward-looking statements regarding trends, our strategies and the anticipated performance of the business. These forward-looking statements will be based on management's current views and expectations and are subject to various risks and uncertainties, including those related to the impacts of COVID-19 on our business, the life sciences industry and global economic conditions.

Our actual results may differ materially. Please refer to the risks listed in our earnings release and the risk factors included in our most recent filing on Form 10-Q, which is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Forward-looking statements made during the call are being made as of today, August 27, 2020, based on the facts available to us today. If this call is replayed or viewed after today, the information presented during the call may not contain current or accurate information.

Veeva disclaims any obligation to update or revise any forward-looking statements. We will provide guidance on today's call but will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum. The guidance we will provide today is in part based on our current assumptions as to the macroeconomic environment in which we will be operating in the future, including the timing and pace of recovery from any negative effects caused by COVID-19. Such matters that are beyond our control and our assumptions may not be correct and may change rapidly.

On the call, we will also discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A reconciliation to comparable GAAP metrics can be found in today's earnings release and in the supplemental investor presentation, both of which are available on our website. A reconciliation can also be found as an exhibit to the Form 8-K filed with the SEC just before this call. With that, thank you for joining us, and I will turn it over to Peter.

Peter Gassner -- Chief Executive Officer

Thank you, Rick, and welcome, everyone, joining us today. Q2 was a strong quarter. Total revenue was $354 million, up 33% year-over-year. Subscription revenue grew 31% year-over-year, and non-GAAP operating margin was 41%.

We're also raising our full-year total revenue guidance to $1.42 billion on the top end, which is above the initial guidance we provided in March. This reflects improved visibility into the back half of the year now that we've had more time to understand how the life sciences industry is adapting to COVID-19. Our life sciences customers reported that the second quarter was as expected with fewer patient visits, delayed procedures and the reversal of Q1 stockpiling. They see some areas improving and are more optimistic as they look to the second half.

More clinical trials are starting back up as clinical research sites reopen. Of the studies that were disrupted, roughly half have now restarted. Crossix data shows that in-office patient visits are trending up from a low of 52% of pre-COVID levels to 84% at the end of July. At the same time, telehealth visits are at 10% of total visits.

While this is down from a peak of 30% a few months ago, it is significantly higher than the 1% before the pandemic. Overall, the industry is rethinking their approach to digital, and this aligns well with our current offerings and future strategy. One of the newer areas that's created a lot of excitement is MyVeeva. MyVeeva is the overall brand of our two consumer-facing applications, one targeted to patients in clinical trials and one for doctors.

This is important new territory for Veeva and for the industry as we provide better ways for our customers to serve patients and doctors online. I talked about MyVeeva for clinical trials on our last earnings call. And this quarter, I will give an update on MyVeeva for Doctors. We announced MyVeeva for Doctors at Veeva Commercial Summit in June.

MyVeeva for Doctors, a website and mobile application, can make it easier for doctors to connect with life sciences. It will provide a single place where doctors can go to get information, services and contact directly from life sciences companies in a standard, easy-to-use format. Today, there is no single place for doctors to go for this. MyVeeva for Doctors has the potential to be a game changer.

This product will be available at the end of the year for the U.S. market, and we're currently in discussions with a handful of potential early adopters. This type of innovation and product leadership in commercial has allowed us to expand our position as a strategic partner to the industry and gain market share. We recently won two significant TM deals for the domestic teams in a large Japanese pharma company.

Veeva Approved Email and Veeva Engage Meeting usage is increasing, and our virtual events business in the Physicians World is gaining momentum. Overall, customers are looking to Veeva as they define their digital engagement strategy. They appreciate the partnership we've provided since the earliest days of pandemic, with Veeva teams going the extra mile, our product innovation and our support with programs like free Engage Meetings, which we extended now through the end of the year. In the data area, I also wanted to provide a quick update on Veeva Data Cloud.

We're now working with three early adopters for our U.S. longitudinal patient data. This is our first Data Cloud offering, and general availability is targeted for December. Leadership in the data market will take many years, but we are confident in our strategy and encouraged by early progress.

The market needs innovation and alternatives to their legacy provider. Looking ahead in commercial, I have never been more excited. We are well-positioned for the future and continue to increase our leadership position as we bring real innovation and partnership to our customers. Before I move to Vault, a brief update on our antitrust trial against IQVIA.

For years, IQVIA has used illegal tactics to maintain their data monopoly and leverage that monopoly to benefit their software business. This harms customers, patients and Veeva. Commercial Cloud products impacted include Veeva Network, Nitro and Andi. We filed our antitrust case in 2017, and we remain confident in our case.

Due to COVID-19-related court delays, we now expect the case to go to trial near the end of 2022. On the Vault side, customers increasingly look to Veeva as they work to streamline drug development. We are seeing this across every area of Veeva Development Cloud. Vault QualityDocs and Vault QMS both had record quarters.

Two top 20 pharma selected QMS and one top 20 selected QualityDocs as their enterprise standards. It was also a great quarter for regulatory. A top 20 pharma made the decision to adopt the full RIM suite, and another top 20 will deploy Vault Registrations globally. Momentum is building in Clinical as well.

This is one of the areas of greatest need for our customers to modernize. For instance, in CTMS, which is the heart of clinical operations technology, we had an outstanding quarter. We now have more than 70 Vault CTMS customers in just three years since we released the product. In the second quarter, we had our first go live with a top 20, added another top 20 and signed our first top seven CRO.

We also had CTMS pilot start at two additional top 20 pharma. We are also making good progress on the clinical data side. More than 100 studies have now started on Vault CDMS. Customers appreciate the innovation and agility that Veeva CDMS brings, as well as the benefit of the integration with Vault eTMF and Vault CTMS.

In the quarter, we had a win with a second top 20 pharma, who will run a handful of complex oncology trials on CDMS. If successful, this could lead to a broader deployment. I'm really excited about Clinical. Our leadership position in clinical operations continues to expand.

We're making great progress in clinical data, and there is a lot of interest in MyVeeva for clinical trials. Clinical is a large area, and it's all coming together nicely. Finally, I'd like to share an update on our efforts outside of life sciences. The industries we serve continue to be impacted by the pandemic, but I'm encouraged by the success we're having with existing customers who continue to expand their use of Veeva.

For instance, a top CPG company will replace an established incumbent with our quality applications across all their business units. Additionally, we continue to make progress with new customers. A top 20 agrochemicals business has selected regulatory solutions as their enterprise standard. Overall, the team had a strong quarter and is executing well.

Before closing, I want to give special thanks to Tim. This is his last earnings call with us, and I'm grateful for his many years of partnership. Tim is staying with Veeva on a part-time basis going forward as an advisor and mentor to the Veeva team. Finally, I'd like to acknowledge all the Veeva employees for their innovation and creativity to come up with new and better ways to continue to support customers.

And I'd like to thank our customers for their tireless efforts to fight this pandemic and to improve the lives of patients around the globe. I'm looking forward to deepening Veeva's partnership with our customers for many years to come. With that, I'll turn it over to Tim.

Tim Cabral -- Chief Financial Officer

Thanks, Peter. As Peter mentioned, the life sciences industry remains relatively healthy overall, and our customers are confident in their outlook for the second half of the year. After working through key business continuity projects in the spring, many of our customers have refocused on core operations and continue to make technology investments to support long-term growth. Against this industry backdrop, we saw strong demand across our product portfolio in Q2.

Commercial Vault had a great quarter, and QualityDocs had its strongest bookings performance ever. We saw increased uptake for products like QMS and CTMS, which are gaining broader adoption. In addition, services demand was particularly resilient in R&D across a range of implementations of Veeva Development Cloud applications. Taken together, these factors helped drive meaningful revenue outperformance in Q2.

Strong demand also drove our bookings outperformance, which, coupled with our strong services demand, resulted in a calculated billings total that was $25 million above our guidance for the quarter. This included subscription yields closed in Q2, which were expected later in the year. Calculated billings also benefited from better-than-expected billing duration for the new business closed in Q2 and fewer-than-expected customer requests for billings changes. Another dynamic that shaped the quarter was the favorable hiring environment for Veeva.

We added a record 357 net new employees in Q2. Our hiring was boosted by the new class of Generation Veeva, our university hiring program that primarily feeds our product and services teams. We are committed to investing in the business and have an aggressive hiring plan for the back half of the year. Additionally, in Q2, operating margin saw a 250-basis-point benefit from travel-related cost savings and lower customer event expenses.

Given the ongoing uncertainty around the pandemic, we expect to see continued cost savings in these areas for the rest of the year, although not quite at this level of benefit. Turning to guidance. Our outlook is informed by the improving environment for our customers and continued growing demand for our products and services, though, as we discussed last quarter, we remain mindful of certain customer segments and industry dynamics that continue to face COVID-19-related headwinds. Please note that combined, these segments represent a small portion of our overall business.

For the full year, we now expect total revenue to be $1.415 billion to $1.42 billion. This increase brings our full-year guidance ahead of the outlook we provided during our fourth-quarter call back in early March. Subscription revenue is expected to be about $1.155 billion for the full year. Commercial Cloud subscription revenue is anticipated to be roughly $585 million, with the Crossix contribution unchanged at $76 million to $78 million.

Meanwhile, full-year Vault subscription revenue is expected to be roughly $570 million. While the headlines we saw in Q1 somewhat persisted with Crossix and Physicians World, both performed in line with our expectations for the second quarter. Advertising spend is rebounding, and virtual events are starting to see momentum. But neither of these businesses are near pre-COVID-19 levels, so our full-year total revenue guidance of $90 million to $95 million remains unchanged.

Our full-year non-GAAP operating income is projected to be between $540 million and $545 million, a non-GAAP operating margin of roughly 38%. Full-year EPS is expected to be $2.64 to $2.67 on a fully diluted share count of approximately 163 million. Looking ahead, we've revised our full-year calculated billings up to $1.5 billion from $1.48 billion, the high end of our previous guidance. We anticipate calculated billings of about $245 million for the third quarter.

Please remember that there are numerous factors that make year-over-year comparisons of this metric highly variable on a quarterly basis. Therefore, we do not believe it is a good indicator of the underlying momentum of our business, and we do not manage it internally. Our subscription revenue guidance and calculated billings guidance for the full year are the best indicators of our momentum. We are also raising our guidance for full-year cash flow from operations excluding the excess tax benefit to $475 million, up from $450 million previously based upon the strong demand we are seeing and our expected full-year billings.

For Q3, total revenue is expected to be $360 million to $362 million, with subscription revenue contributing about $295 million. Non-GAAP operating income is projected to be $138 million to $140 million, and non-GAAP EPS is expected to be $0.66 to $0.68 based on a fully diluted share count of approximately 163 million. Before I close, I would like to take a moment to express my thanks. First, I want to thank Peter, Matt and the board for giving me this amazing opportunity and entrusting me with the role of CFO.

Thanks to our leadership team for being great partners over the past 11 years, and the entire Veeva team for the incredible execution, spirit of innovation and teamwork and always living our values. Lastly, I would like to thank my team for their focus on excellence in the work they do every day. Today, I am as bullish as ever for the opportunity Veeva has in front of it and the impact we are making with our customers in such a mission-critical industry. I'm extremely confident I am leaving Veeva in capable hands with Brent and my leadership team.

Thanks for joining us today. And now I'll turn it over to the operator for questions.

Questions & Answers:

Operator

[Operator instructions] Our first question is from Brad Sills with Bank of America Merrill Lynch. Your line is open.

Brad Sills -- Bank of America Merrill Lynch -- Analyst

Great. Thanks, guys. And, Tim, congratulations on your new role. You'll be missed.

You've been a big help over the years.

Tim Cabral -- Chief Financial Officer

Thanks, Brad.

Brad Sills -- Bank of America Merrill Lynch -- Analyst

Yes. Absolutely. So my question is really just on CDMS and Clinical. Obviously, you had a large, it sounds like, top 20 deal there.

I know the focus has been on kind of building the referenceability and the feature set to go after that category. Do you feel like you're kind of there at this point? Should we expect more of these kinds of deals coming for CDMS?

Peter Gassner -- Chief Executive Officer

Yeah. Brad, I'll take that one. Yeah. These are complex areas, Clinical.

I do feel that we're incrementally growing the business, yes. The product is getting more mature. We're getting some more reference customers. It's early.

Still in CDMS, it's early. It's a big broad area, but I feel like we're on the right track. The core of CDMS, the electronic data capture part, is starting to become pretty mature in this product, but there's a lot of new things in Clinical, too, like MyVeeva for Clinical Trials. So we're doing well.

I'm really happy with it.

Brad Sills -- Bank of America Merrill Lynch -- Analyst

That's great. That's great. Thanks. Thanks so much, Peter.

And then outside life sciences, a chemical win here. It sounds like agrochemical. Is that the first of its kind in this industry? I know you've previously talked about CPG and cosmetics. Should we view that as a potential catalyst for that segment of the outside life sciences?

Peter Gassner -- Chief Executive Officer

Outside life sciences, I would say, our two strong verticals, CPG and cosmetics. We do have some chemicals, including agrochemicals. We have a handful of agrochemical customers now. Nothing has changed there.

I would say CPG and cosmetics is still our main focus.

Brad Sills -- Bank of America Merrill Lynch -- Analyst

Got it. Great. Thanks so much, Peter.

Peter Gassner -- Chief Executive Officer

Thank you.

Operator

Our next question is from Saket Kalia with Barclays. Your line is open.

Saket Kalia -- Barclays -- Analyst

OK. Great. Hey, guys, thanks for taking my questions here. And let me echo my congrats here for you, Tim.

Tim Cabral -- Chief Financial Officer

Thank you, sir.

Saket Kalia -- Barclays -- Analyst

Sure. Maybe first for you, Peter. Can you just talk a little bit about what you think is driving the increased adoption of Quality? Is this something where more reference customer success is maybe helping to broaden that adoption? Or is there something else you feel like is prompting customers to replace what they were using before in favor of something like Veeva Quality?

Peter Gassner -- Chief Executive Officer

It's a great question. I think there's a number of factors. I couldn't point to exactly one, but it's a combination of we've now filled out the suite. We have QualityDocs for the SOP management.

We have the quality management system for the CAPA deviations, those types of things. And we also have Training. All in one unified platform. Nobody's had that before so it was a little bit hard for customers to understand at first.

Now people are seeing early adopters do it. That's creating a lot of interest. I think actually, COVID provides us a little bit of boost because it's, OK, everybody in the life sciences, there's more need to access things remotely, and we perform -- that's one thing about Vault. It performs exceedingly fast remote.

We measure the performance from the end users' browser time, and that's all around the world. The average time to view a document is less than one and a half seconds. That's unheard of, of their existing systems. So these things are providing momentum.

But one thing to know, Quality is maybe our most conservative customer segment, very conservative. So the fact that we're moving fast in this conservative segment is really outstanding.

Saket Kalia -- Barclays -- Analyst

That's great. That's great. Maybe for my follow-up for you, Tim. Can you just talk a little bit about what looked like healthier professional services gross margin? I imagine some of that is maybe from things like higher utilization, maybe some more remote engagements.

But I'm curious maybe how Physicians World is impacting that, if at all.

Tim Cabral -- Chief Financial Officer

Yeah. I think you've hit the nail on the head in terms of the two primary drivers to what we saw in terms of professional services margin this quarter. Just to recap, strong demand leading to really strong utilization. And at the same time, we really don't have any travel cost in a business that has a bit of travel most of the time, Saket.

So you see the bottom line benefit of that in our services gross margin. Physicians World, while, as I said, they did in line with what we expected, it really doesn't move the needle in terms of the size of that business relative to the overall size of our professional services. But they did well in Q2.

Saket Kalia -- Barclays -- Analyst

Got it. Very helpful. Thanks, guys.

Operator

Next question is from Tom Roderick with Stifel. Your line is open.

Tom Roderick -- Stifel Financial Corp. -- Analyst

Great. Thank you for taking my questions. I appreciate it. Tim, we'll miss you.

It's been fantastic working with you. So best of luck on the next adventures for you. I guess the question, I'd love to dive in a little bit deeper. And Peter, you can kind of handle this as you think about the big picture that's going on with spending trends and then the big picture that's going on with net new trials and activity across the space.

Obviously, the strategic picture looking out one, two, three years is very, very favorable. In the near term, I'm sure there's some caution about when do we pull the trigger on net new purchases and IT. Can you just kind of talk about how the strategic conversations you're having with buyers are thinking longer term and manifesting themselves more near term with respect to your portfolio? I'm particularly interested on how that sort of plays out on the Vault side.

Peter Gassner -- Chief Executive Officer

Yeah. Tom, I think high level, important to know life sciences has got a long view on these things. It could take 10 years to bring the drug to market, product has a 20-year life cycle. So they have a long-term view to start with, and that hasn't changed.

We don't see project delays or anything like that. We do see customers sometimes shift priorities a little bit. They may have COVID-related emergencies, which might relate to Veeva or non-Veeva. And when they relate to Veeva, that causes a little burst of business for us.

When it relates to non-Veeva, that might delay one of our existing projects. But all in all, it's good. They're looking for efficiency and digital. So I think it's a very good thing for us, and it feels nice and steady.

It feels to me like life sciences has totally found their way and is comfortable with COVID. They know they have to contribute majorly for society, and it's causing this burst of innovation, and they can see their way through it.

Tom Roderick -- Stifel Financial Corp. -- Analyst

Yeah. Fantastic. That's great. And you've shown some enthusiasm now for a couple of quarters on MyVeeva.

Really excited to hear that that's coming out later in the year. Can you sort of share with us how that might play out from a model perspective or even just a pricing perspective to how customers will pay for this and users can access it? So thinking about one side of this being accessed for clinical trial patients and then the other side for doctors. Take us through how this plays out in the model and then the go-to-market on this as you start to roll this out at the end of the year.

Peter Gassner -- Chief Executive Officer

Yeah. We're very excited about it. And you're right, it's new for Veeva, right, these applications for consumers, patients in clinical trials and doctors. In terms of the model, we won't be charging the doctors or the patients directly for that, right? We'll monetize that through providing benefit for life sciences.

And then as far as the details of exactly how and when and size of that, it's just a little bit too early to go into that. We're really forming the product with our early adopters, and that's what we'll focus on. Customer success first. There's a tremendous amount of value there, and we'll be able to monetize that in a reasonable way as we go forward.

Tom Roderick -- Stifel Financial Corp. -- Analyst

Great. Fantastic. We look forward to more of that. Thank you very much.

I appreciate it.

Peter Gassner -- Chief Executive Officer

Thanks, Tom.

Operator

Next question is from Stephanie Davis with SVB Leerink. Your line is open.

Stephanie Davis -- SVB Leerink -- Analyst

Hey, guys. Congrats on the quarter. And let me echo, Tim, congrats on a well-deserved move-on. So I was hoping you could dive in a little bit deeper into the new wins for longitudinal patient data.

Were they de novo or competitive takeaways? And what pushed these clients over the finish line given it's relatively new introduction?

Peter Gassner -- Chief Executive Officer

Yeah. The longitudinal patient data, I'll take that one. This is Peter. These were not takeaways.

I guess they're competitive. That's for sure. These were people that were looking to analyze patient data to answer some questions that they haven't been able to answer before. So they're specific to a brand.

So they would have looked at other data sets and decided to go with ours partly because they have strong partnerships with Veeva and they're looking for innovation. They're unsatisfied with data sets that they get today. Well, maybe that's too strong, maybe not unsatisfied. They feel like there's something better out there so they're going along on this journey with us.

But the main thing to know about the early adopters, the main thing is not the sale. It's the partnership and the working together to help improve and shape the early product. That's what I'm really excited about. We're getting feedback that's just invaluable from these early adopters.

Stephanie Davis -- SVB Leerink -- Analyst

Understood. And then pivoting a bit to the reiterated guidance for Crossix and Physicians World. Just with the pandemic continuing longer than many of us expected, have you found any alternative ways to monetize and grow the virtual events business just given events are still ongoing?

Peter Gassner -- Chief Executive Officer

Yeah. We're pretty bullish on that. So we have some uptick in business in the virtual events, and I think that's something we're looking forward to partnering with our customers as they go forward because, yes, everybody is realizing that, a, pandemic is here a little longer than we initially expected. And the power of digital is really being impressed on people.

So we're pretty excited about our plans there.

Stephanie Davis -- SVB Leerink -- Analyst

OK. Understood. Thank you for that update.

Peter Gassner -- Chief Executive Officer

Thank you.

Operator

Our next question is from Joe Vruwink with Baird. Your line is open.

Joe Vruwink -- Baird -- Analyst

Great. Hello, everyone, and I'll also extend my best wishes to Tim. Peter, I wanted to go back to your comments on never being more excited around commercial suite. And I guess, are there things when you refer to just life science customers having more visibility within the last couple of months, are there things about Veeva's visibility into particular areas of commercial, where maybe there's some things which actually are driving the comment that you've never been more excited? And you touched on a few things, virtual events and maybe the ability to integrate that into Engage and create this broader set of products.

That maybe is one area. But if you could just dive into maybe any specific things that are perhaps new in the last few months.

Peter Gassner -- Chief Executive Officer

Well, my planning horizon or the things I get excited about are usually a little longer term, right? So 2025 is my focus. And I would say that's what I'm excited about. I feel like commercial, we're going to add a ton of value to our customers as we go toward 2025, and it's a combination of things. One is I feel like we have potential to really do impactful things here in digital, not only with Engage, but with MyVeeva and with virtual events.

So that is pure technology-based value that is added to the customers on the commercial side. And then the data, Data Cloud. That's a very large market, very strategic. And I can see the innovation we're bringing and the feedback from the early customers.

So that's also important. And then the partnership, how the partnership in, basically, the pandemic in this time of stress is causing Veeva and our customers to get closer together. And I would say just the last thing, the hiring, not only the experienced hiring but the awesome new graduates that we're bringing into the company and teaching them the right way and our policies and procedures around that. So sometimes you work really hard and things come together, and the timing is right, and maybe there's some sprinkling of good luck.

But I'm just optimistic about our future.

Joe Vruwink -- Baird -- Analyst

OK. That's helpful. I want to shift gears and have a question on profitability. With Veeva already being back above the 40% kind of high watermark, are there things other than you touched on professional service margins already.

Other things beyond just the strong top line performance providing greater leverage because, as you brought up, you're still doing a good amount of hiring. And I'm curious, are there other upside drivers in the model?

Tim Cabral -- Chief Financial Officer

Yeah. Hey, Joe. This is Tim. The other area that we saw benefit in the quarter to the tune of about 250 basis points was the fact that we had very little travel-related expenses and we moved all of our customer events to virtual.

So those both materially impacted -- well, the tune of 250 basis points impacted the operating margin performance for Q2. As we look out in the year and given the uncertainty of the pandemic, we do expect savings across those two expense lines, Joe, to continue, not at the level we saw likely in Q2. Probably a little bit less than that.

Joe Vruwink -- Baird -- Analyst

That is helpful. Thank you, both.

Operator

Our next question is from Sterling Auty with JP Morgan Chase & Co. Your line is open.

Sterling Auty -- J.P. Morgan -- Analyst

Yes. Thanks. Hi, guys. Tim, congratulations on a great tenure.

I'm just kind of curious if you could answer a question I'm getting frequently from investors just to level set people. As you think about COVID-19, investors are looking at Vault and wondering how many new Vaults might be starting up just to support COVID research and how many of the clinical trials you might be benefiting from. So they're looking for, is there a way to quantify the COVID-19 benefits that you might be seeing?

Peter Gassner -- Chief Executive Officer

Hey, Sterling. This is Peter. I'll take that one. I don't have exact numbers for you.

A very small portion of our work is specific to COVID-19. Now it's important and it's strategic. And so we've done clinical trial work, where the team has had to really hustle and work the weekends, and our technologies really help. But in terms of business or financial, it's a very small portion.

COVID-19 overall is very important. But if you look at life sciences overall, it's a small portion of life sciences revenue.

Sterling Auty -- J.P. Morgan -- Analyst

Great. And then one quick follow-up. The MyVeeva for Doctors, can you give us what do you think is going to be the biggest use case? High level, I understand, I think, its intention. But what do you expect the biggest use case to be for that solution?

Paul Shawah -- Senior Vice President of Commercial Cloud

Hey, Sterling. This is...

Peter Gassner -- Chief Executive Officer

Yes. Paul, why don't you take that one?

Paul Shawah -- Senior Vice President of Commercial Cloud

Yeah. I want to take that one. All right. So this is Paul Shawah.

Thanks for the question. Yes. I mean this is a really significant one. It's a different approach to digital.

What we're doing here, I view this as a platform that's going to lead us and lead the industry in kind of that kind of next direction and next innovation in digital space. If you think about the problem that it's solving, most doctors, they deal with multiple different pharma companies. And from those pharma companies, they probably are dealing with multiple different brands. Every pharma company would love to be in the pocket of every HCP, accessible BNF or accessible via website.

But when you multiply that out, it's the law of large numbers. You end up with the fact that it's too complex for the doctor. They can't be able to engage digitally with so many different companies because they'd have to download so many apps. They'd have to go to so many different websites, remember so many different passwords.

We're putting all of that into one place. We're making it really easy for the doctor to access the entire industry all in one place on an app or on a website. And we're doing digital differently from the standpoint that there's a human relationship involved. There's a human being, the rep or the medical science liaison or some person from the life sciences company, who's creating a connection with the HCP.

And what that means is once they create a connection, they're able to do certain things. They're able to chat. They're able to share information. They're able to request samples.

So as we talk about this with some prospective early customers, we've had a ton of interest after we've announced this. They're really interested in use cases of secure communication, so how do they interact with customers in a secure way that is compliant. So things like a text message may not be so compliant. But doing it via MyVeeva would be.

They're looking to do things like schedule more Engage Meetings with them. They're looking for ways to be accessible by that doctor to do things like requesting samples on the right terms. So really the big problem that we're solving is we're making it easy for the doctor to access life sciences when and how they want to and to enhance the relationship that they have with their reps. That's really the way to think about it.

Sterling Auty -- J.P. Morgan -- Analyst

Excellent. Thank you so much.

Operator

Next question is from Ken Wong with Guggenheim Securities. Your line is open.

Ken Wong -- Guggenheim Securities -- Analyst

Sorry about that, mute. You guys have previously focused primarily just on pharma, biotech customers. Should we view MyVeeva as sort of a one-off push into consumer? Or do you guys have grander aspirations to expand into that particular market?

Paul Shawah -- Senior Vice President of Commercial Cloud

Yeah. So this is an interesting one. When doctors think about their practice and the products that they use for their patients, they don't necessarily think, hey, this is just pharma or just a med device or they think about the full portfolio of products that could be applicable to their patients. Now, which could lead us down a path over time for us to enabling us as a solution for HCPs that are able to interact more broadly with life sciences companies, the consumer and med device.

Having said that, that's certainly a long-term play and something that we would -- a long-term vision that we would grow into. The focus for us today is purely on the life sciences companies. Remember, what we're doing here is life sciences is our customer. We're enabling a lot of the capabilities and the processes that they have or that they need to improve.

That's really our focus. But there is some potential longer term and -- but that's not what we're thinking about today. We're really thinking about the pure life sciences, traditional pharma, biotech customer that we serve.

Ken Wong -- Guggenheim Securities -- Analyst

Great. Thanks, Paul. And then, Tim, couldn't let you leave without asking you a question. As we think about the 3Q calculated billings guide, $245 million, I guess, look, a little light of Street.

Help us understand, I guess, how much of that is maybe a pull forward into Q2. I think you mentioned early signings. Any potential kind of realignments or kind of one-off things we should be aware of in terms of the seasonality in the back half?

Tim Cabral -- Chief Financial Officer

Yeah. Hey, Ken. So those are the two drivers there in terms of a bit of pull forward of deals we thought were going to close in Q3 got pulled into Q2. And then the other thing we talked about in the last two quarters is a better billing duration in Q1 and Q2, which means that those underlying seasonal renewal bases in Q1 and Q2 increase at the expense of the Q3 seasonal renewal base.

So compared to last year, secure renewal base, we're seeing it slightly lower as we see a little bit more movement toward Q1 and Q2.

Ken Wong -- Guggenheim Securities -- Analyst

Got it. Thanks for the color.

Tim Cabral -- Chief Financial Officer

Yep, Thank you.

Operator

Our next question is from Rishi Jaluria with D.A. Davidson. Your line is open.

Rishi Jaluria -- D.A. Davidson -- Analyst

Hey, guys. Thanks so much for taking my questions. And, Tim, I'll echo everyone else and wishing you the best and it's been a great pleasure working with you over the years. I want to start by asking about virtual conferences.

So you had a few of them, if I'm not mistaken, commercial and whatnot. Given how referenceability is so important to the Veeva way of having customers share best use cases, share your best practices, how has it been from having virtual conferences and being able to have some level of referenceability in networking and being able to replicate that in a virtual environment? And I've got a follow-up.

Peter Gassner -- Chief Executive Officer

Yeah. It's working well. It's working well. There are pros and cons.

First, I do recognize we have good relationships with our customers, and those are developed largely in the face-to-face day. So to some extent, we're utilizing that. We wouldn't -- maybe are we -- is it more difficult to develop new relationships in the virtual world? I think it is a bit. Now having said that, we're on the same footing with everyone else.

So I think they're getting used to that, and we're executing very well on our event. But we're looking forward to seeing our customers in person again.

Rishi Jaluria -- D.A. Davidson -- Analyst

Great. That's helpful. And then, Tim, when you quantify the 250 bps of savings from effectively $0 of P&E and not having physical events, and I appreciate that you're quantifying that. I think you're the first I've seen in software to actually try to put a number on that.

But going even beyond this year, so we think post-COVID, if things do return back to something resembling normal, how sustainable are these levels of cost savings? In other words, is there kind of a more permanent shift to doing virtual selling in certain cases, doing virtual implementations and training versus, again, doing that in person? Just how do we think about the sustainability of some of the cost savings that we're realizing around this environment?

Tim Cabral -- Chief Financial Officer

Yeah, Rishi. I certainly don't want to lean into any guidance for next year. But I do think you're hitting on a point in terms of the way we will work in the future. You heard Peter just talk about -- you asked him the question about our customer events, and we certainly enjoy the engagement with our customers when we're face-to-face with them.

And I would imagine our plan is to move those back to what they were before. On the travel side, I do think that you're going to see some benefit. And I would say that across all companies, you're going to see some benefit because during this time, companies have had to get incredibly effective at using virtual means to connect. Does that save -- instead of having three people travel to a customer, do you have one person and two people are connected via Zoom in the future, I think all of those are possible, Rishi.

And I think we will benefit like other companies will benefit, albeit not to the extent we're certainly seeing during this pandemic time.

Rishi Jaluria -- D.A. Davidson -- Analyst

Great. That's really helpful. Thank you.

Operator

Our next question is from Stan Zlotsky with Morgan Stanley. Your line is open.

Stan Zlotsky -- Morgan Stanley -- Analyst

Perfect. Thank you so much guyst. Well, one question at a very high level. It's been a little over a year since Medidata was acquired.

What have you seen from them during that time? Because also in the meantime, you guys have managed to win two top 20 pharma Phase three -- two customers since the acquisition. Maybe just qualitative comments on what you're seeing there. And then I have a quick follow-up.

Peter Gassner -- Chief Executive Officer

Stan, this is Peter. Medidata is a strong competitor. They're the leader by market share in the space. We have not seen obviously a lot of change as it results to the Dassault acquisition.

So we really focus on our own area. And that's this innovation that's bringing the whole clinical suite together from clinic operations integrated tightly with clinical data management, things that we're doing with the clinical database and now MyVeeva for Clinical Trials. So I'm not seeing particular changes from Medidata. They're still a strong competitor.

Stan Zlotsky -- Morgan Stanley -- Analyst

OK. Perfect. And just wanted to make sure that Tim was grilled appropriately on billings before he left. Just following up on Ken's question, could you help us maybe quantify some of the pull forward that you saw on billings into Q2? And also maybe some of the concessions that you guys talked about in Q1 and Q2, any quantification there? I appreciate it.

Thank you.

Tim Cabral -- Chief Financial Officer

Sure. Stan, thanks for the question. So probably on the first one, pull forward as it relates to billings, you're talking about in the few millions area, not more material than that. We went into the pandemic with probably a thought like most companies, Stan, that there would be some requests from our customers around cash flow and billings changes.

Overall, we're not really seeing that very much. We didn't see it too much in back half of Q1, and we didn't see it very much in Q2. Where we are seeing it is in some of the segments that I talked about, Stan, in the Q1 call, some of the customer segments that we're seeing. But it's not as much as we would have expected, which I think is a testament to overall life sciences remains relatively healthy compared to other industries that other companies may be engaged with, Stan.

Stan Zlotsky -- Morgan Stanley -- Analyst

Got it. Thank you.

Peter Gassner -- Chief Executive Officer

Sure.

Operator

Next question is from Brian Peterson with Raymond James. Your line is open. Brian Peterson with Raymond James. Your line is open.

Brian Peterson -- Raymond James -- Analyst

Sorry, confused by the mute button again, but congratulations on the strong results. And Tim, we will miss you on these calls, absolutely. But so just kind of -- and by the way, no billings questions for me. But just starting out on OLS, it sounds like you're adding to the customer base.

I'm just curious what you've learned about some of the customers and the product fit and maybe competitive dynamics in those markets. And when we should think about some accelerated go-to-market investments in outside of life sciences?

Peter Gassner -- Chief Executive Officer

Hi, Brian. This is Peter. I'll take that one. What we've learned is our product fit is really working, where we're focusing the quality in the regulatory area.

And we've kind of honed our motion into these industries. In terms of go-to-market, that will be gradual expansion as we go forward. Now remember, this cosmetics, CPG, it's a big market and our products in there are good, but this is a reasonable-sized market. This is about as big as the clinical data management market inside life sciences.

So we'll see steady increases, but nothing drastic.

Brian Peterson -- Raymond James -- Analyst

Understood. And maybe just one question as it relates to geographies. I know with COVID-19, I think there's different trends across different markets. I'm curious, have you seen that manifest in your business at all? Just looking to get more color on things by geography.

Thanks, guys.

Peter Gassner -- Chief Executive Officer

Yeah. By geography, I think we're pretty steady. We haven't seen things. Now we see difference in interactions, right? In Asia, things have largely gone back to normal in many ways.

They're meeting customers in person, employees getting together. U.S., not so much. Mostly Europe, not. But in terms of financial performance or business activity, no change to the geographic mix.

Operator

Our next question is from Sandy Draper with Truist Securities. Your line is open.

Sandy Draper -- Truist Securities -- Analyst

Thank you very much. Most of my questions have been asked. Maybe just a follow-up, and this is probably for Paul. On your comments around MyVeeva for Doctors, and you're talking about how a pharma company can partner up and get information.

I'm trying to understand if a doc has the app on a phone and you have there four different pharma companies, are there four different instances of the app? Or I'm just trying to understand logistically. I mean is the product setup where it's one product for the customer, for the doctor, but you can have however many pharma companies sign up pushing information and interacting with the customer? Or how does that get separated out between the different pharma companies?

Paul Shawah -- Senior Vice President of Commercial Cloud

Yeah. That's a good question. And that is precisely the magic, what you just described right there. In fact, it's one app on the device.

That's why it's so powerful as one app and it's one website, and they can be invited by one company and create a connection and then they're on it. So one analogy, one thing that you may think about from your everyday world is LinkedIn. Once you're on LinkedIn, you're on LinkedIn once. And you have one profile on there, and then you can start to connect with people.

MyVeeva will have much of that same kind of model, where a doctor will get invited, they'll create and set up an account one time, and then they'll be able to connect with anybody across all of life sciences through a single application. So that's precisely why it's different and why it's so unique in the industry because nothing else really exists like that. And then that relationship, the reason why -- one of the things that we see pretty consistently is that kind of pure digital stand-alone without a relationship versus digital combined with a relationship, the combination with the relationship, it's an order of magnitude more effective. So the perfect example for that is when you look at the engagement rate with an email sent by a human being, let's say, Approved Email versus the engagement rate from a corporate home office, it's much, much higher with Approved Email because of that relationship.

And that's also another kind of key point with MyVeeva. It's combining digital with human relationships. So yes, a really good, insightful question.

Peter Gassner -- Chief Executive Officer

Yeah. OK. And I'll pile on there. Like Sandy, one thing we think about is this amazing contact manager, you go in there and you search, you're searching for a brand, a company or a person.

And you find it, and then you find all the things that are connected to that. That's the way to think about it, absolutely. Kind of revolutionary really.

Sandy Draper -- Truist Securities -- Analyst

Got it. That's really helpful commentary from both of you, guys, and that's actually my only question. Don't have a follow-up. So I'll step back in the queue.

Peter Gassner -- Chief Executive Officer

Thanks, Sandy.

Operator

Our next question is from Tyler Radke with Citi. Your line is open.

Tyler Radke -- Citi -- Analyst

All right. Peter, I think this question is for you. I wanted to ask about the CRO customer. I think you signed a CTMS deal with your first top seven CRO.

And I believe a quarter ago, you were kind of a bit more cautious just on the CRS segment in general. Obviously, they were facing some kind of greater COVID headwinds than the rest of your customer base. But maybe just walk us through that selection process. How you kind of see the CRO opportunity, where we are and how big that ultimately could evolve to?

Peter Gassner -- Chief Executive Officer

CRO is very important for us. Both yes. They will use our software, but they're also a channel particularly for our clinical data management area, right? They would sometimes do clinical data management for customers, small and large. Yes, we were a bit cautious on the CROs because of their business got hit by COVID because they couldn't get out there, trials being stopped.

That's a pretty immediate hit. In terms of this deal or more broadly CTMS in the CRO area, they're doing it. And this customer, in particular, is doing it for increased efficiency. That's one.

They have a lot of people. CTMS is the heartbeat of it. Their process and system that they had before was not fast, it's not configurable, it's not user-friendly, and they couldn't get the information out of it if they wanted to. So it's about efficiency.

And the other part is they're realizing that Veeva is connecting things together into a clinical network, and our clinical data management system is quite promising. So there's a need for the CROs to be close to Veeva, unless they would like to, and some do, right? A couple tried to develop their own technologies. But I think most are realizing that it's probably better to align with an industry standard technology, which Veeva is becoming.

Tyler Radke -- Citi -- Analyst

Helpful. And my follow-up, I just wanted to better understand kind of the linearity or just business trends by quarter. Obviously, it sounds like here in the second quarter, you saw a notable improvement from Q1 trends. But kind of curious if there was kind of a step function increase in any given quarter or if it's gradually increasing, improving trends by quarter and whether you've seen that kind of continue to go up into the right through August so far.

Tim Cabral -- Chief Financial Officer

And Tyler, this is Tim. Just so I'm clear, are you talking about how the trends are shaping as -- or during the pandemic? Is that what you're asking about specifically?

Tyler Radke -- Citi -- Analyst

Yeah. Just kind of business activity by quarter -- or sorry, by month throughout your Q2. And then, obviously, now we're into your Q3, has that kind of continued if it was kind of steadily improving business trends?

Tim Cabral -- Chief Financial Officer

Yeah. I think that -- I guess, I would say, and Peter, I don't know if you want to add to this. I guess what I would say is we really have never had a strong linearity in a quarter as you see some software companies have. We work with our customers, and they engage with us and buy from us when they need new users, new products and the like.

As it relates to the pandemic, there was probably a bit of a pause as customers and software companies like Veeva got used to the new way that we are going to work during the time, Tyler. And that was a short pause, I would say. And I would say coming out of Q1 primarily into our Q2, we've seen continued good demand, and I would say that continues into early August.

Tyler Radke -- Citi -- Analyst

Thank you.

Operator

Our last question comes from David Larsen with Verity. Your line is now open.

David Larsen -- Verity Research -- Analyst

Hi, Tim. I think you mentioned in your prepared remarks that you had the best bookings quarter ever in one of your line items. Did I hear that correctly? And what was that line item? And what drove that performance? Thanks.

Tim Cabral -- Chief Financial Officer

Yeah. Sure, Dave. So it was QualityDocs, which is in the Development Cloud area and the Quality area. It is the content management-based application that focuses on all the documentation and documents needed to manage your quality environment within pharma.

So a very important part of the Quality area. And I think it's a combination probably of a couple of things. One, this is an area we have become the clear leader in, and I think you're seeing some enterprise companies leaning in as it's becoming a priority for them. And secondly, we've seen quite a nice uptake in this area around the SMB market, the longer tail for the opportunity we have in front of us for the Development Cloud and products like this.

So combination of a couple of things and really underlining the fact that we're the leader in this area as we're moving forward.

David Larsen -- Verity Research -- Analyst

OK. And then just one quick follow-up. For the MyVeeva for Docs, it's -- like great description on what that actually does. It sounds like there's a lot of value there.

Can you talk about the patient side of it? Like patients can already sort of dial in and sort of record how they're responding to certain meds. They can already sort of record, I think, through the Internet how they're responding to certain meds on a clinical trial. How does the MyVeeva for patient side working? What's sort of new and novel about that?

Peter Gassner -- Chief Executive Officer

MyVeeva for patients, they can do some things electronically. But for example, well over 80% of just what's called the electronic consent, meaning the patient giving their consent to medical procedures right through data, etc. About over 80% of that is done by paper signatures in practice. So it's really fragmented, and there's quite a few different applications for quite a few of these different things.

So it's not a great world. It's much easier to buy something on amazon.com than it is to go through a clinical trial as a patient. And that's what it's about, bringing it all together for the patient.

David Larsen -- Verity Research -- Analyst

OK. And just one last one. For IQVIA, where are you seeing them in the market most frequently? Like where do you see them? And how do you compete with them most frequently in the market? Thanks.

Paul Shawah -- Senior Vice President of Commercial Cloud

Yeah. We primarily see IQVIA on the commercial side. We don't see them so often in the R&D space. Given what they're kind of going to market with, they've had a particular focus on, as you know, the data side primarily focused on commercial.

And then also, they announced some software applications in commercial. So we tend to see them there most, but not so much in R&D.

David Larsen -- Verity Research -- Analyst

Great. Thanks so much.

Operator

And this does conclude the Q&A period. I'll now turn it back over to Peter for any closing remarks.

Peter Gassner -- Chief Executive Officer

Thank you, operator. I'd like to take this time to say thank you again to Tim Cabral. When our Veeva venture started together, Tim was our part-time bookkeeper, and Veeva was an infant. And now 13 years of partnership later, here we are, a company that's contributed in a major way to our customers, employees, investors and society in general.

And throughout that, Tim has been steady and strong like a rock throughout the journey, and he's built an amazing team. So Tim, you get my vote for CFO of the decade. Thank you. And thanks to everyone for joining us today, and I look forward to talking with you again at Investor Day online on October 29.

Have a great evening. Goodbye.

Duration: 60 minutes

Call participants:

Rick Lund -- Head of Investor Relations

Peter Gassner -- Chief Executive Officer

Tim Cabral -- Chief Financial Officer

Brad Sills -- Bank of America Merrill Lynch -- Analyst

Saket Kalia -- Barclays -- Analyst

Tom Roderick -- Stifel Financial Corp. -- Analyst

Stephanie Davis -- SVB Leerink -- Analyst

Joe Vruwink -- Baird -- Analyst

Sterling Auty -- J.P. Morgan -- Analyst

Paul Shawah -- Senior Vice President of Commercial Cloud

Ken Wong -- Guggenheim Securities -- Analyst

Rishi Jaluria -- D.A. Davidson -- Analyst

Stan Zlotsky -- Morgan Stanley -- Analyst

Brian Peterson -- Raymond James -- Analyst

Sandy Draper -- Truist Securities -- Analyst

Tyler Radke -- Citi -- Analyst

David Larsen -- Verity Research -- Analyst

More VEEV analysis

All earnings call transcripts